Related references
Note: Only part of the references are listed.Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Jun Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, 0X40, GITR, CD27, CD28, and ICOS
Miguel F. Sanmamed et al.
SEMINARS IN ONCOLOGY (2015)
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab
Serena S. Kwek et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Fine-Needle Aspiration is Superior to Needle Core Biopsy as a Sample Aquisition Method for Flow Cytometric Analysis in Suspected Hematologic Neoplasms
Jonathan Dale Boyd et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2014)
Ward's Hierarchical Agglomerative Clustering Method: Which Algorithms Implement Ward's Criterion?
Fionn Murtagh et al.
JOURNAL OF CLASSIFICATION (2014)
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
Lei Lu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
Saskia J. A. M. Santegoetst et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
Saskia J. A. M. Santegoets et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
Stephen R. Goding et al.
JOURNAL OF IMMUNOLOGY (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui-Ru Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Intraprocedural Evaluation of Fine-Needle Aspiration Smears: How Good Are We?
Rachel Factor et al.
DIAGNOSTIC CYTOPATHOLOGY (2012)
Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators
Bernd Bodenmiller et al.
NATURE BIOTECHNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Utility of Flow Cytometry Immunophenotyping in Fine-needle Aspirate Cytologic Diagnosis of Non-Hodgkin Lymphoma A Series of 252 Cases and Review of the Literature
Anna Demurtas et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2010)
Role of fine-needle aspirate immunophenotyping by flow cytometry in rapid diagnosis of lymphoproliferative disorders
Ritu Gupta et al.
DIAGNOSTIC CYTOPATHOLOGY (2007)
Fine needle aspiration is a feasible and accurate technique in the diagnosis of lymphoma
RM Austin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Utility of fine-needle aspiration as a diagnostic technique in lymphoma
ST Hehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
